About me
Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company is deeply established in the burn industry with treatment options for patients along the severe burn spectrum; Epicel® (cultured epidermal autografts) and NexoBrid® (anacaulase-bcbd). Epicel is an autologous treatment for adult and pediatric patients with deep dermal or full-thickness burns comprising a total body surface area of ≥30% and NexoBrid is an effective enzymatic agent for eschar removal for deep partial thickness and/or full thickness burns in adult and pediatric patients.
